A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

NCT05806099 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: MBS303

Sponsor

Beijing Mabworks Biotech Co., Ltd.